APRE:NSD-Aprea Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 26.45

Change

0.00 (0.00)%

Market Cap

USD 0.56B

Volume

0.08M

Average Target Price

USD 34.00 (+28.54%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aprea Therapeutics, Inc., a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD58.95B 22.22 16.42
REGN Regeneron Pharmaceuticals, Inc

N/A

USD54.85B 18.84 14.36
MRNA Moderna, Inc

N/A

USD50.27B N/A N/A
SGEN Seagen Inc

N/A

USD30.27B 63.87 62.62
ALXN Alexion Pharmaceuticals, Inc

N/A

USD27.10B 28.74 26.73
RPRX Royalty Pharma plc

N/A

USD26.01B 22.60 9.61
BNTX BioNTech SE

N/A

USD25.27B -99,999.99 N/A
BGNE BeiGene, Ltd

N/A

USD25.02B N/A N/A
GMAB Genmab A/S

N/A

USD23.59B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing APRE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -42.36% 19% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.36% 19% F 9% F
Trailing 12 Months  
Capital Gain 5.04% 46% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.04% 45% F 52% F
Trailing 5 Years  
Capital Gain 64,412.20% 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 64,412.20% 100% A+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A 100% A+
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return 41.94% N/A N/A 64% D
Market Capitalization 0.56B 65% D 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.99 43% F 28% F
Price / Cash Flow Ratio -20.98 78% C+ 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -75.00% 42% F 15% F
Return on Invested Capital -81.16% 34% F 11% F
Return on Assets -39.46% 26% F 8% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.77 43% F 27% F
Short Percent 17.96% 13% F 12% F
Beta -0.78 99% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector